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useful as pharmaceutical agents for oral or intravenous 
administration to patients su?en'ng from acute central ner 
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central nervous system oxidation which can exhibit itself as 
progressive central nervous system function loss. 
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2,4-DISULFONYL PHENYL BUTYL 
NITRONE, ITS SALTS, AND THEIR USE AS 
PHARNIACEUTICAL FREE RADICAL TRAPS 
BACKGROUND OF THE INVENTION 
This invention relates to a particular nitrone compound 
and its salts and their advantageous use as pharmaceutical 
nitrone free radical trapping agents. 
BACKGROUND INFORMATION 
Alpha-phenyl tert butyl nitrone 
O 
or “PBN”) was identi?ed in the 1970s as a useful analytical 
reagent to be used in conjunction with electron spin reso 
nance (“ESR”) to aid in the detection of free radicals. PBN 
was found to react with certain free radicals and generate a 
chemical species yielding a characteristic ESR spectrum and 
thus making it possible to determine the presence or absence 
of free radicals 
In the late 1970s and early 1980s the medical community 
began to focus on the roles played by free radicals in 
diseases such as heart attacks, strokes and the like. PBN was 
used increasingly in vitro to provide analytical evidence of 
the presence of free radicals in these settings. It was also 
later administered in vivo in animal models, again as an 
analytical adjunct in attempts to observe free radicals during 
ischemia simulations and the like. 
In the mid 1980s, the ?rst possible therapeutic eifects of 
PBN were implied when severe trauma ischemia animal 
tests showed that PEN-treated animals were more likely to 
survive than controls. 
On May 2, 1991, our PCT patent application WO-9l 
05552 was published. This patent application, which in part 
corresponds to now-issued US. Pat, Nos. 5,025,032 and 
5,036,097, described PBN and a family of PBN derivatives 
de?ned by the formula 
H O 
\ / 
C=N+ wherein 
/ \ 
X Y 
X is phenyl or 
(011)» 
where R is H, 
0 
ll 
Z—C— 
or Z; or 
O 
—CI—I=N 
Y 
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and n is a whole integer from 1 to 5 or 
and Y is tert-butyl or a hydroxylated or acetylated tert-butyl 
or a substituted phenyl. These compounds were proposed as 
pharmaceutical agents to treat the aftermath of stroke and 
other conditions reported to be associated with free radical 
damage. 
In 1992 we ?led a second PCT patent application on PBN 
and related compounds and their medical use. This applica 
tion, based on prior US. patent application Ser. No. 716,952 
(?led Jun. 18, 1991) and abandoned on Apr. 26, 1993, was 
published on Dec. 23, 1992 as WO 92/22290. This 1992 
publication provided two extremely broad and general dis 
closures. First, it attempted to describe as many disease 
states as possible which were associated with free radicals. 
These ranged from CNS conditions (including stroke, aging, 
migraine, etc.) through peripheral organ disease (including 
atherosclerosis, bed sores, wounds, and muscle overexer 
tion) through UV exposure, to mention but a few highlights. 
Second, it attempted to list as many potential spin traps as 
possible. 
In addition to a whole range of non-PEN materials, this 
application greatly expanded the de?nition of potentially 
useful PBN compounds to include PBN, and derivatives 
thereof of the formula 
wherein 
X is phenyl, imidazolyl, phenothiazinyl or 
(112)” 
n=1—5, preferably l—3; 
R2=independently (can vary within the molecule) halogen, 
alkyl, oxyalkyl, alkenyl, oxyalkenyl, OH, NHZ, NHZ, 
NZZ, NO, 
—SO3H, —OSO3H, SH, —S(alkyl), —S(alkenyl, and 
haloalkyl, speci?cally including —CF3; 
AIO or S; and 
Z is a C1 to C6 straight, branched, alkyl or cyclic group; and 
Y is a tert-butyl group that can be hydroxylated or acetylated 
at one or more positions; phenyl or 
5,488,145 
(112)" 
PBN was stated to be the most preferred compound at that 
time, being said to have no measurable effect on normal or 
uninjured cells, and a number of derivatives were also stated 
to be useful, including hydroxy derivatives, especially 2-, 3- I 
or 4-hydroxypheny1 t-butyl nitrone and phenyl (mono-, di 
or trihydroxy) tert-butyl nitrone; PBN esters, especially 
esters which release 2-, 3-, or 4-hydroxyphenyl t-butyl 
nitrone such as acetoxy derivative; 2-, 3-, or 4-carboxyphe 
nyl t-butyl nitrone; phenyl hydroxybutyl nitrone; alkoxyl 
derivatives, especially alkoxyl derivatives which release 2-, 
3-, or 4-hydroxyphenyl t-butyl nitrone, for example, the 2-, 
3-, or 4-methoxyphenyl derivatives of PBN; and acetarnide 
derivatives, especially acetamide derivatives which release 
2-, 3-, or 4-aminophenyl t-butyl nitrone; diphenyl nitrone 
(PPN) and the analogous diphenyl nitrone derivatives; 
N-tert-butyl-ot-(4-nitro-phenyl) nitrone; and N-tert-butyl-ot 
(2-sulfophenyl) nitrone. 
STATEMENT OF THE INVENTION 
We have now discovered that one particular PBN deriva 
tive and its salts have unexpectedly superior pharmacologi 
cal properties. Although this derivative, 2,4-disulfonyl PBN, 
falls within the broad family of materials generally 
described in the aforementioned WO 92/022290 publication, 
it is not speci?cally disclosed. Neither are its advantageous 
properties predicted. 
The present compound with its two sulfonate groups was 
expected to exhibit improved water solubility but was also 
expected to exhibit poor transport across the blood/brain 
barrier because of its lipophobic character. However, when 
the present compound was made and tested in vivo, it 
showed an unexpected increase in e?icacy as compared to 
PBN. This increase in efficacy occurred along with an 
increase in potency as compared to PBN. In direct contrast 
to this marked increase in potency and e?icacy there was a 
marked and highly signi?cant decrease in toxicity as com 
pared to PBN. 
These results were unexpected because in the general 
literature on structure/activity relationships within speci?c 
de?ned families of compounds therapeutic potency typically 
covaries with toxicity. Thus, most related compounds main 
tain their ratio of therapeutic potency to toxicity. In contrast, 
the compound of this invention deviates from this expected 
relationship when its potency increased and its toxicity 
decreased relative to closely related analogs. 
Accordingly, in one aspect, the invention provides the 
PBN-disulfonyl compound 
0. 
| 
3031-1 
and its pharmaceutically acceptable salts. 
In a second aspect, the invention provides intravenously 
and orally-administrable pharmaceutical compositions hav 
ing this compound or its salt as active ingredient. 
In a third aspect, this invention provides a method for 
treating a patient who is suffering from a condition involving 
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acute oxidative damage to the central nervous system, such 
as a patient who has suffered a stroke, in which a pharma 
ceutical composition based on this compound or its salt is 
administered intravenously. 
In a fourth aspect, this invention provides a method for 
treating a patient suffering from a condition characterized by 
protracted low grade oxidative stress upon the central ner 
vous system and progressive loss of central nervous system 
function. In this method, a pharmaceutical composition 
based on this compound or its salt is administered intrave 
nously or preferably orally. 
DETAILED DESCRIPTION OF THE 
INVENTION 
This Detailed Description is arranged into the following 
sections: 
Brief Description of Drawings. 
The Compounds and Salts. 
Compound Preparation. 
Pharmaceutical Compositions. 
Conditions Treated and Treatment Regimens. 
Examples. 
BRIEF DESCRIPTION OF THE DRAWINGS 
In this speci?cation reference will be made to the accom 
panying drawings in which 
FIG. 1 is a schematic ?ow chart of the reactions used to 
prepare the compound. 
FIGS. 2 (A, B and C) and 3 (A, B, C, and D) are two sets 
of graphs illustrating the undesirable change in animal body 
thermal regulatory ability which occurs as a function of dose 
level with a prior art nitrone radical trapping agent and 
contrasting this with the lack of such undesired toxic effect 
with the compound of the invention. 
FIG. 4 (A, B, C, and D) is a set of four graphs demon 
strating the superiority of the compound of the invention as 
compared to a closely related prior art nitrone compound in 
the treatment of gradual neurodegeneration conditions (such 
as Alzheimer’s disease) as illustrated by their relative ability 
to interfere with beta amyloid protein’s inactivation of key 
enzymes in solution. 
The Compound and Salts 
The compound of this invention is 2,4-disulfonyl ot-phe 
nyl tertiary butyl nitrone. It is also referred to informally 
herein as “2 4-disulfonyl PBN” or “PBN 2,4-disulfonate.” It 
exists in an acid form 
as a solid and in solution in low pH conditions. It also exists 
at higher pHs in an ionized salt form which can be shown as 
5,488,145 
5 
-continued 
01' HS 
0. 
where X is a pharrnaceutically acceptable cation. Most 
commonly, this cation is a monovalent material such as 
sodium, potassium or ammonium, but it can also be a 
multivalent alone or cation in combination with a pharma 
ceutically acceptable monovalent anion, for example cal 
cium with a chloride, bromide, iodide, hydroxyl, nitrate, 
sulfonate, acetate, tartrate, oxalate, succinate, palmoate or 
the like anion; magnesium with such anions; zinc with such 
anions or the like. When these combinations of a polyvalent 
cation and a monovalent anion are illustrated in structural 
formulae, herein, the monovalent anion is identi?ed as “Y”. 
Among these materials, the free acid and the simple 
sodium, potassium or ammonium salts are most preferred 
with the calcium and magnesium salts also being preferred 
but somewhat less so. 
Compound Preparation 
As detailed in FIG. 1 and demonstrated in Example 1, the 
compound of this invention can be prepared by a two step 
reaction sequence. In the ?rst step, commercially available 
tertiary butyl nitrate (Z-methyl-Z-nitropropane) is converted 
to the corresponding n-hydroxyl amine using a suitable 
catalyst such as an activated zinc/acetic acid catalyst or an 
aluminum/mercury amalgam catalyst. This reaction can be 
carried out in 0.5 to 12 hours and especially about 2 to 6 
hours or so at a temperature of about 15° to 100° C. in a 
liquid reaction medium such as alcohol/water mixture in the 
case of the zinc catalyst or an ether/water mixture in the case 
of the aluminum amalgam catalyst. 
In the second step, the freshly formed hydroxylamine is 
reacted with 4-formyl-1,3'benzenedisulfonic acid, typically 
with a slight excess of the amine being used. This reaction 
can be carried out at similar temperature conditions. This 
reaction is generally complete in 10 to 24 hours. 
The product so formed is the free acid and is characterized 
by a molecular weight of 89 g/mole. It is a white powdery 
material which decomposes upon heating. It is characterized 
by a solubility in water of greater than 1 gram/m1 and a 1H 
NMR spectrum in D20 of 8.048 ppm (dd, 8.4, 1.7 Hz); 8.836 
ppm (d, 8.4 Hz); 8.839 ppm (d, 1.7 Hz); 8.774 ppm (s). 
The various salts can be easily formed by admixing the 
free acid in aqueous medium with two equivalents of the 
appropriate base, for example, KOH for the potassium salt, 
and the like. 
Pharmaceutical Compositions 
The compound (including its salts) can be formulated into 
pharmaceutical compositions suitable for oral or intravenous 
injection administration 
The compositions for oral administration can take the 
form of liquid solutions or suspensions, powders, tablets, 
capsules or the like. In such compositions, the PBN 2,4 
disulfonate or its salt is usually a minor component (0.1 to 
say 50% by weight) with the remainder being various 
vehicles or carriers and processing aids helpful for forming 
the desired dosing form. A liquid form may include a 
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suitable aqueous or nonaqueous vehicle with buffers, sus 
pending dispensing agents, colorants, ?avors and the like. 
A solid form may include, for example, any of the 
following ingredients, or compounds of a similar nature: a 
binder such as microcrystalline cellulose, gum tragacanth or 
gelatin; an excipient such as starch or lactose, a disintegrat 
ing agent such as alginic acid, Primogel, or corn starch; a 
lubricant such as magnesium stearate; a glidant such as 
colloidal silicon dioxide; a sweetening agent such as sucrose 
or saccharin; or a ?avoring agent such as peppermint, sugar, 
methyl salicylate, or orange ?avoring. 
In the case of injectable compositions, they are commonly 
based upon injectable sterile saline or phosphate-buffered 
saline or other injectable carriers known in the art. Again the 
active nitrone is typically a minor component, often being 
from about 0.05 to 10% by weight with the remainder being 
the injectable carrier and the like. 
Conditions Treated and Treatment Regimens 
The conditions treated with the 2,4-disulfonyl PBN gen 
erally fall into two groups. The ?rst includes conditions 
involving acute intense oxidative damage to a region of the 
central nervous system. Examples of these conditions 
include stroke, conditions associated with stroke, concus 
sion and subarachnoid hemorrhage. In this setting, the 
compound is administered in manners designed to get the 
drug into the patient’ s bloodstream as quickly and directly as 
possible. This usually means intravenous administration. 
Intravenous dose levels for treating these conditions range 
from about 0.1 mg/kg/hour to at least 10 mglkg/hour, all for 
from about 1 to about 120 hours and especially 24 to 96 
hours. A preloading bolus of from about 10 to about 500 mg 
may also be administered to achieve adequate steady state 
levels. 
An unexpected and key advantage of 2,4-disulfonyl PBN 
is that it can be administered at vastly higher levels than are 
possible with PBN itself. As will be shown in the Examples, 
doses of up to 1000 mg/kg/hour and higher or intravenous 
bolus doses of from 10 to 2500 mg/kg have been demon 
strated to be possible with PBN-2,4-disulfonyl or its salts 
while with PBN itself death or acute toxicity results from 
such doses. With 2,4 disulfonyl PBN there is an unexpected 
positive continuance of the dose/response curve in these 
high dose levels with the clear message that intense heavy 
dosing immediately post stroke or other trauma may in many 
cases provide a major positive impact upon recovery. 
The second group of conditions which respond favorably 
to 2,4-disulfonyl PBN treatment are conditions character 
ized by protracted low grade oxidative stress upon the 
central nervous system and gradual progressive central 
nervous system function loss. These conditions include 
Alzheimer’s disease, Parkinson’s disease, amyotrophic lat 
eral sclerosis (ALS), mu1ti~infarct dementia, retinopathy and 
the like. Each of these conditions is characterized by a 
progressive loss of function. 2,4-disulfonyl-PBN or its salts, 
when administered orally or intravenously, can slow and 
possibly reverse the loss of function. If intravenous admin 
istration is desired, similar levels to those used with acute 
conditions but at the lower end of the ranges are generally 
used. 
In these cases, the regimen for treatment may stretch over 
many months or years so oral dosing is preferred for patient 
convenience and tolerance. With oral dosing, one to three 
oral doses per day, each from about 0.02 to about 50 mg/kg 
5,488,145 
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are called for with preferred doses being from about 0.04 to 
about 5.0 mg/kg. 
Of course, one can administer 2,4-disulfonyl PBN as the 
sole active agent or one can administer it in combination 
with other agents. 
EXAMPLES 
EXAMPLE 1 
Synthesis of 2,4-disulfonylphenyl-N-t~butylnitrone 
(Compound “I” in subsequent Examples). This preferred 
synthesis is based on the work by R. H. Hinton and E. G. 
Janzen (J. Org. Chem. 57:2646-2651, 1992). As shown in 
FIG. 1 it involves the condensation of an aldehyde with a 
hydroxylamine. The hydroxylamine is unstable and is pre 
pared fresh on the day of use using an activated zinc catalyst. 
The synthesis is as follows: 
Prerequisite Chemicals 
1. 95% Ethanol 
2. 2-Methyl-2~nitropropane 
3. Zinc dust 
4. Glacial acetic acid 
. Diethyl ether 
6. Saturated sodium chloride 
7. Magnesium Sulfate, Anhydrous solid 
8 4-Formyl-l,3-benzenesulfonic acid (MW 310.21 
g/mole), disodium salt, hydrate 
9. Methanol 
10. Dichloromethane 
Procedure 
Preparation of N-t-Butylhydroxylamine 
1. A 500 mL three neck round bottom ?ask is equipped 
with a magnetic stir bar, thermometer adapter, ther 
mometer, and addition funnel. 
2. 95% ethanol (350 mL) was added to the ?ask and 
cooled to 10° C. in an ice bath. 
3. 2-Methyl-2-nitropropane (6.18 g, 0,060 mole), and zinc 
dust (5.89 g, 0,090 mole) were added in single portions. 
4. Glacial acetic acid (10.8 g, 0,180 mole) was placed in 
the addition funnel and added dropwise at such a rate 
with vigorous stirring to maintain the temperature 
below 15° C. 
5. The ice bath was removed and mixture was stirred for 
3 hrs at room temperature. 
6. The solvent was stripped from the mixture, leaving 
t-butylhydroxylamine, zinc acetate, and water. 
7. Dichloromethane (50 mL) was added and the mixture 
?ltered through a Buchner funnel. 
8. The zinc acetate cake left on the ?lter paper was washed 
with 2X25 mL dichloromethane. 
9. Water was separated from the ?ltrate in a separatory 
funnel and the organic layer dried over magnesium 
sulfate. 
10. The magnesium sulfate was removed by ?ltering 
through ?uted ?lter paper, then dichloromethane 
stripped oil" by rotary evaporation. 
11. The product (100% yield=5.34 g), a viscous liquid, 
was dissolved in methanol (50 mL) for use in part B. 
Preparation of 2,4-disulfonylphenyl-N-t-butylnitrone 
l. A 3-neck 250 ml round bottom ?ask was set up with a 
stir bar, a gas dispersion tube, an addition funnel, and 
1O 
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a Friedrichs condenser cooled with recirculating ice 
water. 
2. To the ?ask were added 200 mL of methanol, 4-forrnyl 
1,3-benzenedisulfonic acid (9.31 g, 30 nnrroles) and 
N-t-butylhydroxylamine (25 mL of the methanol solu 
tion from part A, 30 mmoles theoretical). 
3. The reaction was heated to re?ux with a heating mantle 
While bubbling the reaction with nitrogen with stirring. 
4. The mixture was re?uxed for 2 hours. 
5. The remainder of hydroxylamine from part A was 
added. 
6. Re?uxing was continued with nitrogen bubbling for at 
least 18 hours, but not more than 24 hours. 
7. The hot reaction mixture was ?ltered on a Buchner 
funnel, and the solid washed with hot methanol. 
8. The methanol was stripped off by rotary evaporation to 
a yellow, viscous oil. 
9. Hot 1:1 ethanol:acetone (200 mL) was added and the 
mixture heated to dissolve the oil. 
10. The solution was cooled to crystallize the product. 
11. The product was collected on a Buchner funnel and 
dried under vacuum overnight. 
12. The reaction typically gives 75% yield of I, a white 
powder. 
EXAMPLE 2 
Alternate Synthesis of 2,4-disulfonylphenyl-N-t-butylni 
trone (Compound 1). This is an earlier-developed method 
which used to prepare samples of the compound used in 
several of the experiments reported in the Examples of this 
speci?cation. The product of this Example is identical in all 
ways to the product of Example 1. This synthesis method is 
as follows: 
Prerequisite Chemicals 
1. Aluminum Foil, cut into 5 cm wide strips and rolled in 
a ca. 1 cm diameter cylinder 
2. Mercury (H) Chloride (9.68 g in 476 ml water) 
3. Ethanol 
4. Ether (6 L) 
. Pure Water 
. 2-Methyl-2-nitropropane 
. Sodium Hydroxide, 2M (80 g in 1 L water) 
. Magnesium Sulfate, Anhydrous solid 
4-Formyl-1,3-benzenesulfonic acid (MW 310.21 
g/mole) 
Procedure 
Preparation of N-t~Butylhydroxylamine 
1. Aluminum foil cylinders were dipped into HgCl2 
solution for 15—30 seconds, then dipped in ethanol, 
then dipped in ether and then placed into a 5L ?ask 
containing 500 ml of diethyl ether and 21.4 ml of water. 
2. The ?ask was ?tted with a 250 ml pressure-equalizing 
dropping funnel, a mechanical stirrer, a nitrogen inlet, 
and a Friedrichs condenser cooled with recirculated ice 
water. 
. The mixture was stirred for 10 minutes. 
4. 2-Methyl-2-nitropropane (71.68 g, 75.5 ml) was added 
using the dropping funnel at such a rate as to maintain 
a vigorous re?ux. 
NOTE: Addition must be completed in less than 20 
minutes or the yield drops signi?cantly. 
5,488,145 
5. As the addition proceeded, ether was added in 500 ml 
portions. This was done to maintain as high a concen 
tration of product as possible without the formation of 
a gel. Up to 2 L of ether can be added with no 
deleterious effects on the yield. 
6. Once addition of 2-methyl-2-nitropropane was com 
plete, the reaction was stirred for an additional 30 
minutes. 
7. The resulting gray suspension was suction ?ltered in 3 
batches to remove aluminum salts. 
8. Each ?lter cake was washed with 1 L of ether. 
9. The combined either layers were washed with 300 ml 
of 2 M NaOH, then dried (MgSO4), and concentrated 
in vacuo to leave a soft white solid. 
10. The solid melts just above room temperature, but 
could be dried further in a vacuum oven (no more than 
a few minutes), leaving 38 to 45 g of solid. 
11. The solid can be used as is or was puri?ed by 
recrystallization from pentane. 
12. Molecular weight-89 g/mole. 
B. Preparation of 2,4-disulfonylphenyl-N-t-butylnitrone 
1. A 250 m1 ?ask was equipped with a stir bar and a 
Friedrichs condenser cooled with recirculated ice 
water. 
2. The ?ask was charged with 71.8 ml of methanol, 14.5 
g of 4-formyl-1,3-benzenedisulfonic acid (46.7 
mmoles, 1 eq.), and 5.0 g of N-t-butylhydroxylamine 
(56.2 mmoles, 1.2 eq.). 
3. The mixture was re?uxed overnight. 
4. The reaction product was transferred to round-bottom 
?ask and rotovaped to dry. 
5. The solid residue was mashed with ether, the ether was 
decanted off (yellow). 
6. Step 5 was repeated. 
7. Product (“I”) was crystallized from methanol following 
a hot methanol ?ltration to remove insoluble precipi 
tates and recrystallized twice from methanol. 
EXAMPLE 3 
A series of experiments were carried out to compare in 
vivo the ef?cacy of 2,4 disulfonyl PBN (“I”), PBN, and two 
monosulfonate PBN compounds as agents for protecting 
against neuron loss following brain ischernia and reperfu 
sion injury. The test procedure is that reported by W. Cao, J. 
M. Carney, A. Duchon, R. A. Floyd and M. Chevion as 
“Oxygen free radical involvement in ischemia and reperfu 
sion injury to brain, Neuroscience Letters, 88 (1988), 233. In 
the experiments a test compound was administered to groups 
of six gerbils i.p. as a single dose 30 min before 5 min 
bilateral carotid occlusion. The density of neuronal nuclei in 
a 100 micron was measured. Two controls were present— 
controls which received no test compound and controls 
which received no test compound and no brain ischemia. As 
illustrated in Table 1. the compound of the invention showed 
unexpected advantages as compared to the prior art mate 
rials. First, it was seen that at low dose levels, such as 3.2 
mg/kg, compound I was 2—3 times as potent at preventing 
neuronal loss. At high does levels it was seen that I was able 
to achieve complete protection against neuronal loss as the 
test brains showed neuronal densities identical to the non— 
ischernic controls. The prior materials were either toxic at 
these dose levels or showed signi?cantly lower degrees of 
protection. These results show a clear increase in potency for 
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neural protection for compound I compared to PBN and two 
closely related analogs and an unexpected decrease in tox 
icity compared to PBN. 
TABLE 1 
Neuronal nuclei/100 micron ?eld 
2- 3 
PBN sulfo sulfo I. 
Non-ischernic control 4.21 4.21 4.21 4.21 
(.43) (.43) (.43) (.43) 
Ischemic control 0.58 0.58 0.58 0.58 
(.28) (.28) (.28) (.28) 
3.2 mg/kg 0.43 0.73 0.35 1.43 
(.18) (.34) (.21) (.31) 
10 mg/kg 1.13 0.68 0.81 2.57 
(.39) (.31) (.40) (.25) 
32 mg/kg 1.83 0.73 1.63 3.53 
(.21) (.31) (.35) (.41) 
50 mg/kg 3.11 1.01 1.63 4.11 
(.29) (.61) (.35) (.43) 
100 mg/lcg 3.68 0.93 1.93 4.18 
(.71) (.53) (.39) (.49) 
320 mg/kg 3.78 1.11 1.78 4.23 
(.43) (.41) (.40) (.39) 
1000 mg/kg Toxic 0.98 1.58 4.11 
(43) (33) (41) 
3200 mg/kg Toxic — — 4.18 
EXAMPLE 4 
A series of experiments were conducted in which com 
pound I was compared to PBN and two sulfonate analogs in 
post-ischemia treatment. The general method described in 
example 1 was used but the test compounds were adminis 
tered i.p. as a single dose 30 min after reperfusion following 
5 min ischemia. The results are summarized in Table 2. They 
show that the compound of the invention is again more 
potent at low doses and more potent and less toxic at high 
doses. Also again, toxicity interferes with the prior art 
materials ability to go to high doses at which levels the 
compound of the invention provides dramatically effective 
therapy. 
TABLE 2 
Neuronal nuclei/100 micron ?eld 
2- 3— 
PBN sulfo sulf I. 
Non-ischemic control 4.18 4.18 4.18 4.18 
(.59) (.59) (.59) (.59) 
Isohemie control 0.85 0.85 0.85 0.85 
(.19) (.19) (.19) (.19) 
32 mg/kg 1.09 ND ND 1.83 
(.31) (.41) 
50 mglkg 1.85 0.68 0.73 2.73 
(.49) (.31) (.34) (.39) 
100 mg/kg 2.11 0.78 1.09 3.41 
(.51) (.23) (.48) (.37) 
320 mg/kg 2.25 0.81 0.93 3.55 
(.43) (.31) (.48) 
1000 mg/kg Toxic ND ND 3.68 
(.39) 
EXAMPLE 5 
Compound I was compared with PBN to determine their 
relative effectiveness for protection of neuronal loss when 
administered i.v. 60 min after reperfusion onset following 5 
min ischemia in gerbils using the general test method 
described in Example 1.. The results are summarized in 
5,488,145 
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Table 3. and illustrate that compound I is of signi?cantly 
greater therapeutic bene?t in a clinical treatment setting 
following injury to the brain. 
TABLE 3 
mg/kg single dose 
N = 6 per group 0.0 0.5 1.0 10 
Saline, no ischemia 4.11 - _ _ 
(.28) 
saline, ischemia 0.93 — _ _ 
(-17) 
PBN — 0.83 1.07 1.23 
(.23) (.29) (.31) 
I. — 1.25 1.75 2.43 
(.19) (.28) (.31) 
Neither PBN nor 1. had an effect on neuronal density in 
control ‘gerbils without brain injury. 
EXAMPLE 6 
Brain injury can manifest itself as behavioral changes. In 
this experiment, young adult (3-4 months of age) gerbils 
were tested to determine their ability to perform an 8-arrn 
maze test 24 hours following an ischemic event as described 
in Example 1. As compared to nonischemic animals, when 
untreated they committed many more errors. PBN and 
compound 1 were administered to some of the test animals. 
As detailed in Table 4. gerbils treated with high doses of 
compound I had error levels indistinguishable from those of 
nonischemic animals. PBN was less effective. This shows 
that compound I can protect against the loss of temporal/ 
spatial short term memory following ischemia (24 hours 
post) errors in 8-arm radial maze test of young gerbils 
following 5 min ischemia. 
TABLE 4 
mg/kg/hr for 24 hours 
N = 6 per group 0.0 1.0 32 50 100 
Control 4.1 —— — — 
(38) 
Postischemic 37.6 — — — 
(4.85) 
PBN — 29.8 18.19 6.23 5.83 
(7.27) (5.83) (.71) (.49) 
I. — 14.63 7.19 4.28 4.11 
(3.81) (.81) (.29) (.19) 
EXAMPLE 7 
The ability of the compound of the invention to reduce 
infarct volume following an ischemic event was determined. 
As detailed in Table 5. it was observed that while PBN and 
compound I were both e?fective at low doses, at high doses 
I gave the best protection and PBN was toxic. Table 5 shows 
the infarct volume observed when test compound was 
administered i.v. 60 min after middle cerebral occlusion and 
continued for 24 hours in C57BL/6J mice. 
TABLE 5 
Posttreatment Infarct Volume in mm3 
(mg/kg/hr) 0.0 1.0 10 100 
Control, no ischemia 0 _ _ _ 
Saline, ischemia 23 _ _. __ 
(2) 
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TABLE 5-continued 
Posttreatment Infarct Volume in mm3 
(mg/kg/hr) 0.0 1.0 10 100 
PBN — 17,7 13.8 TOXIC 
(2.8) (2.3) 
1. — 16.8 12.7 8.3 
(1.7) (3.93) (.71) 
EXAMPLE 8 
In this study, compound I and PBN were compared for 
their ability to impart lethality protection (% survived) in 
aged gerbils (18-24 months of age, n:12/group) from 10 
min ischemia when given 30 min before ischemia. As shown 
in Table 6. compound I was superior at all dose levels and 
achieved complete protection at high levels where PBN was 
only partially e?'ective. 
TABLE 6 
Pretreatment (mg/kg) 0.0 10 32 100 320 
Saline 11 _ ~ _ - 
PBN _ 42 so 75 92 
I. _ 5o 75 100 100 
EXAMPLE 9 
An important advantage of the compound of this inven 
tion as compared to the art-taught compound, PBN, is its 
markedly diminished toxicity. As detailed in Table 7. acute 
lethality in C57BL/6L mice was determined based upon 
varying sizes of single i.p. doses of nitrone. PBN showed 
signi?cant toxicity at 560 mg/kg dose levels. Compound I 
showed no toxicity at doses nearly twenty times as great. 
TABLE 7 
% Survival mg/kg 
n = 20 mice 320 560 1000 3000 10000 
PBN 100 25 0 0 0 
I. 100 100 100 100 100 
EXAMPLE 10 
Another undesirable systemic effect which has been 
observed in vivo with nitrone radical traps is a depression in 
body temperature. This toxicity can have serious health 
consequences and also can complicate diagnosis of other 
conditions. As detailed in FIGS. 2 and 4, the compound of 
this invention was administered to mice and gerbils at levels 
as high as 1000 mg/kg with no measurable temperature 
decrease. In contrast, the compound of the art, PBN, gave up 
to an 8° C. decrease in body temperature at a does of only 
500 mg/kg. 
EXAMPLE 11 
The compound of the invention was tested to determine 
its effectiveness in the treatment of conditions characterized 
by protracted low grade oxidative stress upon the central 
nervous system and gradual progressive central nervous 
system function loss by testing its effectiveness in a model 
for Alzheimer’s disease (“AD”). This model has the follow 
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ing basis: Recent studies have demonstrated that there is an 
age-associated increase in protein oxidation and loss of 
enzyme activities in the brain of aged individuals. Tissue 
cultures of fibroblasts from aged individuals and red blood 
cells of different ages both show an exponential increase in 
protein carbonyl content (a measure of protein oxidation) 
and a decrease in marker enzyme activities. Brain protein 
oxidation progressively increases over the life span of the 
individual. 
The role of abnormal arnyloid precursor peptide process 
ing and metabolism in AD has also been explored in a 
number of different models. In vitro studies using embryonic 
hippocampal neuronal and neuronal/glial cultures have dem 
onstrated that BAP 1-40 produces cytotoxicity over an 
extended period of co-incubation. When this peptide is 
infused into rat brains, lesions are produced. Some of the 
proposed breakdown fragments of BAP are also neurotoxic 
[c.g. BAP (25-35)]. The neurotoxicity appears to be both 
mediated via glutamate receptors, and also by non-glutamate 
receptors mechanisms. Confocal microscopy studies of neu 
ronal cultures have demonstrated that exposure to BAP 
(1-40) results in oxidative stress [Dichloro?uorescein and 
increased intracellular free calcium Fura-Z]. 
In our model it has been demonstrated that BAP fragments 
can directly inactivate glutamine synthetase (GS) and cre~ 
atine kinase (CK) in tissue extracts and in cultured hippoc 
ampal neurons and glia (See A and B in FIG. 4). A and B of 
FIG. 4 present the dose-related inactivation of glutamine 
synthetase and creatine kinase by AP (25-35). Cytosolic 
fractions from gerbil neocortex were prepared and enzyme 
activities determined. Samples were incubated in the pres 
ence of di?erent concentrations of the peptide for 10 min 
prior to assay. Solid symbols represent the effects of the 
naturally occurring 25—35 fragment. Open circles indicate 
that the reverse sequence (32-25) had no effect on enzyme 
activity. Open triangles indicate that the scrambled amino 
acid sequence also had no elfect on enzyme activities, 
compared to the effect of 25—35. Each point is the mean (+/— 
s.e.) of 5 observations. BAP derived and other cellular 
sources of free radicals are an important detenninant of the 
initiation and progression of AD. 
As demonstrated in C and D in FIG. 4, compound 1 and 
PBN each show the ability to protect GS and CK against the 
effects of BAP fragments. C and D of FIG. 4 present the 
protective effects of co-incubation of the cytosolic fractions 
with BAP 25-35 (0.4 mg/ml) in combination with different 
concentrations of PBN (open circles) or compound I (closed 
circles). Each point is the mean (+/— s.e.) of 3 observations. 
As can be seen in C and D, compound I gives complete 
protection and in fact might even be able to reverse the 
effects of oxidation. In contrast, PBN’s effectiveness is quite 
limited as it is asymptotically leveling out at a substantially 
incomplete level of protection. 
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What is claimed is: 
1. 2,4-disulfonyl ot-phenyl tertiary butyl nitrone. 
2. A compound de?ned by the formula: 
0. 
l 
H035 CHZNT C(CH3)3. 
3. A pharmaceutically acceptable salt of 
O_ 
4. The salt of claim 3 having the formula: 
0, 
I 
wherein X is selected from the group consisting of Na, K, 
NH4, Ca, Mg, Zn, ZnY, CaY and MgY, wherein Y is a 
pharmaceutically acceptable monovalent anion. 
5. A pharmaceutical composition comprising the com 
pound of claim 1 in a pharmaceutically acceptable intrave 
nous injectable carrier. 
6. A pharmaceutical composition comprising the com 
pound of claim 1 in a pharmaceutically acceptable oral 
carrier. 
7. A pharmaceutical composition comprising the com 
pound of claim 2 in a pharmaceutically acceptable intrave 
nous injectable carrier. 
8. A pharmaceutical composition comprising a compound 
of claim 2 in a pharmaceutically acceptable oral carrier. 
9. A phannaceutical composition comprising the com 
pound of claim 3 in a pharmaceutically acceptable intrave 
nous injectable carrier. 
10. A pharmaceutical composition comprising the com 
pound of claim 4 in a pharmaceutically acceptable intrave 
nous injectable carrier. 
11. A pharmaceutical composition comprising a com 
pound of claim 3 in a pharmaceutically acceptable oral 
carrier. 
12. A pharmaceutical composition comprising a com 
pound of claim 4 in a pharmaceutically acceptable oral 
carrier. 
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